Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00512070 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 7, 2007
Last Update Posted : April 10, 2019
|
Sponsor:
Seattle Institute for Biomedical and Clinical Research
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Seattle Institute for Biomedical and Clinical Research
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | December 2021 |